Retatrutide: what the human research actually shows (and what I think)
The strongest weight-loss numbers in a published trial I have read, with the biggest asterisk: Phase 2 data, no approval yet, and a mechanism (glucagon activation on top of the dual-agonist backbone) that is genuinely different from what the market is used to.
Why I looked into this
Retatrutide is the first peptide on my list where I have personal experience. I used it for about one month. I want to be careful here because this is the part of the site where opinion lives, and my experience is exactly one person’s. I will put the personal note where it belongs (in the Honest Take section), and I will write the rest of the monograph the way I would for any other molecule.
What I did want to look at was whether the Phase 2 results that produced all the breathless social-media headlines actually hold up on close reading, and how to think about a molecule that is not yet approved but is already on the gray market.
What Retatrutide actually is
Retatrutide is a synthetic peptide engineered to activate three distinct receptors: GLP-1, GIP, and the glucagon receptor. The glucagon receptor arm is the piece that distinguishes it from Tirzepatide’s dual-agonist design. Glucagon activation, in this context, is believed to increase energy expenditure on top of the appetite and gastric-emptying effects that the GLP-1 and GIP arms contribute.
The developer is Eli Lilly, the same company behind Tirzepatide. Retatrutide sits in the Phase 3 pipeline under the TRIUMPH program name. It is not yet approved, it does not have a brand name yet, and it is not available through any pharmacy.
What the human research shows
Do published human trials exist?
Yes, and the Phase 2 results are why the compound is getting attention.
The headline paper is Jastreboff AM et al., NEJM, 2023. A 338-patient Phase 2 trial in adults with obesity, 48 weeks, multiple weekly retatrutide dose arms versus placebo. The Phase 3 TRIUMPH program is ongoing as of April 2026 and has not yet reported final results.
What evidence actually exists?
The key published human data:
- Jastreboff AM et al., NEJM, 2023. 338 adults with obesity (BMI 30 or greater, or 27-plus with a weight-related comorbidity). 48-week Phase 2 RCT. Mean body weight change at the highest-tested dose arm was approximately minus 24.2 percent, versus a small placebo change. That figure exceeds the published obesity-trial results for semaglutide and tirzepatide at comparable time points.
- Rosenstock J et al., NEJM, 2023. Phase 2 in type 2 diabetes. Reported substantial HbA1c reduction across dose arms.
- Phase 3 TRIUMPH program: multiple trials ongoing as of this writing. No final readouts in the regulatory record yet.
What the research does not show
The research does NOT show:
- Phase 3 confirmation. Everything above is Phase 2. Phase 2 results often moderate in Phase 3 at scale.
- Long-term cardiovascular outcomes data. The CV outcomes trial has not been reported.
- Long-term safety in a broad population. The studied cohort is small and the durations are short relative to chronic-use scenarios.
- Durability of weight loss after stopping. The dual- and mono-agonists regain weight after discontinuation. There is no reason to assume the triple agonist does not also regain.
- Equivalence of research-use-only product. Unapproved compounds in the gray market are not the thing that Lilly studied.
Known safety signals in humans
In the Phase 2 obesity trial, the adverse event profile resembled the broader incretin class: nausea, diarrhea, constipation, vomiting, with higher frequency at higher dose arms. The glucagon-receptor activation adds additional theoretical questions (heart rate elevation, effects on glycemic control in susceptible patients) that are being actively monitored in ongoing trials.
What the Phase 2 record does not tell you is what happens at month 18, at month 36, or in the 5-plus percent of the population that will end up on this molecule long-term if it is approved. That record will come from Phase 3 and the post-marketing period, not from today’s papers.
FDA and legal status in the US
Retatrutide is investigational. There is no approved pharmacy pathway to it. The only legitimate way a human in 2026 uses retatrutide is inside an Eli Lilly-run clinical trial under IRB oversight.
The research-use-only gray market is selling retatrutide anyway. Those vials are not the compound that Lilly is running Phase 3 on, in the sense that they are not manufactured under GMP, not independently verified, and not accompanied by the informed-consent framework that a trial provides. The efficacy and safety evidence from the Phase 2 papers does not automatically transfer to those vials.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Retatrutide specifically
Retatrutide is the hardest case for source safety on this entire list, because there is no legitimate reference product to benchmark against. With semaglutide or tirzepatide, a lab can at least run identity testing against a commercial comparator. With retatrutide, the only sources of the authentic molecule are Eli Lilly clinical trial supply. A research-use-only vial labeled retatrutide is not a verifiable version of the trial product.
This is the peptide on my list where the gap between what the studies tested and what the market is selling is the largest and the least checkable.
Cost reality
Research-use-only vials labeled retatrutide trade in the gray market at prices similar to high-end tirzepatide research-use-only supply. There is no pharmacy alternative to compare against, because there is no approved pharmacy product.
Any pricing you see is a number attached to a vial whose contents cannot be verified against a pharmaceutical standard.
Questions worth asking any source
- Where is this material manufactured, and can you provide a certificate of analysis from an independent lab confirming identity at the sequence level?
- How is this material being sold, given that retatrutide is investigational and not available through any US pharmacy?
- What is the shelf life and storage specification for this specific lot?
- Is there any legitimate human-use pathway for this compound outside a clinical trial?
- What is your policy if a customer has an adverse reaction?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have used Retatrutide. For me, it was about one month. The experience was positive in the narrow sense: I felt the effects the Phase 2 papers describe, at lower intensity than the highest trial dose, and I tolerated them without any acute adverse event I could attribute to the compound. That is one person’s subjective report, not evidence that anything in particular works for anyone else.
The thing I want to say plainly is that a triple agonist is not a short-term cut or a quick fix. The mechanism touches glucose homeostasis, appetite, gastric emptying, and energy expenditure simultaneously. That is a serious compound. Thinking about it as a 30-day solution to a summer deadline is the wrong frame. The people in the Phase 2 trial who got the big numbers were on the compound for 48 weeks, with study support, in a controlled protocol. That is the evidence base.
If I were going to use retatrutide again, it would be with a clinician, with baseline labs, with a plan for what success looks like and what stopping looks like, and with a real understanding that this is investigational and the long-term record does not exist yet. The forum discourse frames retatrutide as an already-proven product. It is not. It is a Phase 2 result waiting for Phase 3 to confirm or not confirm.
For someone curious, read the Jastreboff 2023 NEJM paper. For someone considering use, the only legitimate pathway is a clinical trial; everything else is research-chemical-sourced and not the product that produced the Phase 2 numbers. For someone who has already used it, the conversation I would want to have with myself is about the next year, not the next month.
Questions to ask your doctor
If you are considering Retatrutide, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have read the Jastreboff 2023 Phase 2 paper on retatrutide. Do you know the literature, and do you see any clinical trials in my area that are still enrolling?
- If I had used an investigational triple-agonist for a month, what baseline labs would you want to re-check and at what timing?
- Given the glucagon-receptor activation component, are there any cardiovascular or metabolic conditions in my history you would want to flag before I consider any future use?
- What symptoms would make you want me to stop immediately and contact you?
- Is there any legitimate pathway to retatrutide outside a clinical trial that you are aware of in 2026?
- For the approved alternatives (semaglutide, tirzepatide) with a real pharmacy pathway, how should I weigh them against the investigational option?
What to do next
Read the Phase 2 paper
Jastreboff 2023 NEJM on retatrutide obesity Phase 2 is the reference paper. It is worth reading in full, not just the headline number.
Open the primer →Look for a TRIUMPH clinical trial
The only legitimate pathway is an ongoing trial. ClinicalTrials.gov lists active TRIUMPH sites. Bring the visit-prep packet to your clinician.
Get the packet →Understand what you are doing
Research-use-only retatrutide is not the molecule the trials studied. The source-safety framework has no satisfying answer for investigational compounds.
Open the checklist →Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial.” NEJM. 2023;389:514-526. Industry funded (Eli Lilly). PMID 37366315.
- Rosenstock J, Frias J, Jastreboff AM, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator controlled phase 2 trial.” The Lancet. 2023. Industry funded (Eli Lilly).
- ClinicalTrials.gov: TRIUMPH Phase 3 program entries.
- Eli Lilly investor disclosures on the TRIUMPH development timeline.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Tirzepatide
The approved dual-agonist that retatrutide is engineered on top of. Read these two together to understand the mechanistic step up.
Semaglutide
The GLP-1-only product with the strongest long-term and cardiovascular outcomes data. The evidence comparator for the whole class.
Survodutide
Boehringer’s GLP-1 and glucagon dual agonist. The two glucagon-activation stories side by side give you a cleaner mechanistic picture.